Polidocanol is an FDA-approved sclerosant indicated for treating uncomplicated spider veins and reticular veins in the lower extremities. Despite restrictions against compounding drugs that are essentially copies of FDA-approved or commercially available products, polidocanol is also available from compounding pharmacies and outsourcing facilites. Compounded drug products are not FDA-approved and have not undergone premarket FDA review for safety, effectiveness, and quality. Seven samples of polidocanol were obtained from three compounding pharmacies and analyzed using high pressure liquid chromatography. None of the samples contained the labeled concentration of polidocanol and five contained excessive levels of impurities. Since the potency and purity of compounded polidocanol injection cannot be assured, physicians who use these products should consider FDA-approved products to ensure optimal safety and efficacy. J Drugs Dermatol. 2019;18(11):1124-1127.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Attempted ablation of an orbital cyst in a dog with 1% polidocanol using fluoroscopy and contrast cystography.
Vet Ophthalmol
January 2025
Cardiology & Cardiac Surgery, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA.
A 4-year-old female spayed mixed-breed dog received enucleation surgery of the right eye in 2018 following the diagnosis of glaucoma. The patient was presented in 2021 for recurrent swelling of the right orbit. Ultrasound confirmed the presence of a cystic structure, and chemical ablation with 1% polidocanol (compounded, Stokes Pharmacy, Mt.
View Article and Find Full Text PDFLow temperature offers better foam stability.
J Cosmet Dermatol
October 2024
Department of Cardiovascular Surgery, Ankara City Hospital, Ankara, Turkey.
Background: The foam's structural longevity, linked to the effectiveness of sclerotherapy, depends on preparation conditions. The factors enhancing the treatment's effectiveness and efficacy are still under discussion.
Methods: We conducted an in vitro preclinical research, which included 144 independent trials.
Comparative effectiveness of non-compounded polidocanol 1% endovenous microfoam (Varithena) ablation versus endovenous thermal ablation utilizing a systematic review and network meta-analysis.
J Vasc Surg Venous Lymphat Disord
November 2024
Samaritan Hospital, Troy, NY; St. Peter's Vascular Associates, St. Peter's Medical Associates, Albany, NY.
Objective: We compared the effectiveness and safety of polidocanol 1% endovenous microfoam ablation vs endovenous thermal ablation with radiofrequency or laser energy for treatment of venous insufficiency caused by lower extremity truncal vein incompetence via network meta-analysis of published comparative evidence.
Methods: We conducted a systematic literature review following best practices, including a prospective protocol. We screened studies published in English from 2000 to 2023 for randomized and nonrandomized studies reporting direct or indirect comparisons between polidocanol 1% endovenous microfoam and endovenous thermal ablation.
Topical injection of sclerosant to treat cheek subcutaneous venous malformation resulting in blindness: a case report.
BMC Ophthalmol
September 2023
Department of Ophthalmology, Shenyang Fourth People Hospital, Liaoning, China.
Loss of vision after topical injection of sclerosant is a rare and uncommon complication. We describe a case with vision loss following the facial injections of physician-compounded (PCP) foam sclerotherapy which was created by room air. A 3-year-old boy underwent injection of 5ml polidocanol foamed with room air to treat the venous malformation on the cheek near the left orbit.
View Article and Find Full Text PDFFoam-in-Vein: Characterisation of Blood Displacement Efficacy of Liquid Sclerosing Foams.
Biomolecules
November 2022
Department of Pharmaceutics, School of Pharmacy, University College London, London WC1N 1AX, UK.
Sclerotherapy is among the least invasive and most commonly utilised treatment options for varicose veins. Nonetheless, it does not cure varicosities permanently and recurrence rates are of up to 64%. Although sclerosing foams have been extensively characterised with respect to their bench-top properties, such as bubble size distribution and half-life, little is known about their flow behaviour within the venous environment during treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!